Sector Gamma AS Raises Holdings in Bruker Co. (NASDAQ:BRKR)

Sector Gamma AS lifted its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 38.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 308,004 shares of the medical research company’s stock after purchasing an additional 85,000 shares during the period. Bruker comprises approximately 2.3% of Sector Gamma AS’s holdings, making the stock its 17th biggest holding. Sector Gamma AS owned 0.20% of Bruker worth $13,531,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Boston Advisors LLC grew its stake in Bruker by 28.9% in the 2nd quarter. Boston Advisors LLC now owns 58,908 shares of the medical research company’s stock worth $2,942,000 after acquiring an additional 13,203 shares during the period. Janus Henderson Group PLC grew its stake in Bruker by 1.1% in the 2nd quarter. Janus Henderson Group PLC now owns 3,335,079 shares of the medical research company’s stock worth $166,587,000 after acquiring an additional 36,643 shares during the period. Virginia Retirement Systems ET AL purchased a new stake in Bruker in the 2nd quarter worth approximately $340,000. HWG Holdings LP purchased a new stake in Bruker in the 2nd quarter worth approximately $172,000. Finally, Mckinley Capital Management LLC Delaware purchased a new stake in Bruker in the 2nd quarter worth approximately $5,326,000. 66.46% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:BRKR traded up $0.80 during midday trading on Friday, hitting $47.90. 511,900 shares of the company’s stock traded hands, compared to its average volume of 752,409. The firm’s fifty day moving average price is $44.58 and its two-hundred day moving average price is $44.26. The company has a market cap of $7.33 billion, a PE ratio of 34.21, a P/E/G ratio of 2.34 and a beta of 1.36. Bruker Co. has a twelve month low of $26.10 and a twelve month high of $52.23. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.27 and a current ratio of 2.23.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, October 31st. The medical research company reported $0.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.05. The company had revenue of $521.10 million during the quarter, compared to the consensus estimate of $493.52 million. Bruker had a net margin of 10.20% and a return on equity of 28.02%. The company’s revenue was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.37 EPS. As a group, equities research analysts anticipate that Bruker Co. will post 1.62 EPS for the current fiscal year.

In related news, CEO Burkhard Prause sold 15,702 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $42.96, for a total transaction of $674,557.92. Following the completion of the sale, the chief executive officer now owns 1,338 shares of the company’s stock, valued at approximately $57,480.48. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Marc A. Kastner sold 3,203 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $47.39, for a total transaction of $151,790.17. Following the sale, the director now directly owns 7,608 shares of the company’s stock, valued at approximately $360,543.12. The disclosure for this sale can be found here. Insiders sold a total of 66,108 shares of company stock valued at $2,849,941 in the last three months. Insiders own 26.50% of the company’s stock.

A number of brokerages have weighed in on BRKR. Needham & Company LLC set a $58.00 price target on shares of Bruker and gave the company a “buy” rating in a report on Friday, September 27th. ValuEngine upgraded shares of Bruker from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Bank of America upgraded shares of Bruker from a “neutral” rating to a “buy” rating and set a $52.00 price target on the stock in a report on Thursday, September 26th. BidaskClub lowered shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, Zacks Investment Research lowered shares of Bruker from a “hold” rating to a “sell” rating and set a $46.00 price target on the stock. in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company’s stock. Bruker has an average rating of “Hold” and an average price target of $50.70.

Bruker Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Story: Dividend Reinvestment Plan (DRIP)

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.